News & Insights
This is where we share our own and our portfolio companies’ press releases as well as relevant Sunstone articles, analyses and SoMe posts.
5 latest news
5 latest insights
News Archive
MinervaX raises upsized EUR 47.4M Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials
MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announced today that it has raised an upsized EUR 47.4 million Series B financing. The round included new investors Sanofi Ventures, Wellington...
The FDA grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/metastatic melanoma
IO Biotech today announced that the FDA has granted breakthrough therapy designation for a combination of the potential therapy IO102 and IO103 with anti-PD-1 mAb for patients with unresectable/ metastatic melanoma. Press inquiries should be adressed to:...
Kim Stratton, CEO, resigns from Orphazyme
Orphazyme A/S (ORPHA.CO) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that Kim Stratton has decided to resign from Orphazyme following a...
Sunstone announces new investment in neuropsychiatric company Synendos Therapeutics
Copenhagen, 12 November 2020 – Sunstone Life Science Ventures today announces it has invested in a new portfolio company, Synendos Therapeutics AG (“Synendos”), a biopharmaceutical company dedicated to developing novel therapeutics for the treatment of a wide range of...
Sunstone portfolio company Galecto in successful IPO on Nasdaq Global Market in the US.
Sunstone today announced its portfolio company Galecto, a clinical stage biotech firm focusing on novel therapeutics for fibrosis and inflammatory-related lung diseases, successfully has launched an initial public offering (IPO) on Nasdaq Global Market in the U.S....
Sunstone welcomes Novo Holdings A/S as new LP in Sunstone Life Science Ventures Fund IV
Sunstone today announced that Novo Holdings A/S has joined as Limited Partner (LP) in Sunstone’s latest fund; Sunstone Life Science Ventures Fund IV (“Sunstone IV”) Sunstone has been collaborating with Novo Seeds and Novo Ventures, both a part of Novo Holdings, for...
Cantargias valberedning föreslår ny styrelseledamot
Valberedningen i Cantargia AB (publ), som består av Sten Verland (partner i Sunstone Life Science Ventures, ordförande), Jannis Kitsakis (Fjärde AP-fonden), Alexander Mata (Alecta Pensionförsäkring, ömsesidigt) och Magnus Persson (styrelseordförande i Cantargia),...
Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file an MAA with the EMA for arimoclomol in NPC in H2 2020.
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the...
Orphazyme files registration statement in the U.S. in connection with proposed global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe
Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that it has filed a registration statement on Form F-1 with the U.S....
Insights Archive
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Or follow us on LinkedIn
